ENTERA BIO LTD. Increase (Decrease) in Contract with Customer, Liability
ENTERA BIO LTD. (ENTX) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2024-03-08
- ENTERA BIO LTD. increase (decrease) in contract with customer, liability for the quarter ending 2023-12-31 was $0.00.
- ENTERA BIO LTD. increase (decrease) in contract with customer, liability for the quarter ending 2023-09-30 was $0.00.
- ENTERA BIO LTD. increase (decrease) in contract with customer, liability for the quarter ending 2023-06-30 was $0.00.
- ENTERA BIO LTD. increase (decrease) in contract with customer, liability for the quarter ending 2023-03-31 was $0.00.
- ENTERA BIO LTD. increase (decrease) in contract with customer, liability for fiscal 2023 was $0.00.
- ENTERA BIO LTD. increase (decrease) in contract with customer, liability for fiscal 2022 was -$15.00K.
- ENTERA BIO LTD. increase (decrease) in contract with customer, liability for fiscal 2021 was -$143.00K.
- ENTERA BIO LTD. increase (decrease) in contract with customer, liability for fiscal 2020 was -$109.00K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $0.00 derived: sum of 2 quarters · filed 2024-03-08 | $0.00 derived: sum of 3 quarters · filed 2024-03-08 | $0.00 10-K · filed 2024-03-08 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 4 quarters · filed 2024-03-08 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | $0.00 derived: sum of 3 quarters · filed 2024-03-08 | $0.00 derived: sum of 4 quarters · filed 2024-03-08 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-08 | $0.00 derived: sum of 3 quarters · filed 2024-03-08 | $0.00 derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $0.00 derived: sum of 2 quarters · filed 2024-03-08 | $0.00 derived: sum of 3 quarters · filed 2024-03-08 | -$15.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | -$15.00K 10-Q · filed 2023-11-14 | $0.00 derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$15.00K 10-Q · filed 2023-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-08-11 | -$8.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$15.00K 10-Q · filed 2023-05-05 | $0.00 derived: sum of 2 quarters · filed 2023-05-05 | -$8.00K derived: sum of 3 quarters · filed 2023-05-05 | -$15.00K derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $7.00K derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | -$143.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | -$8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$15.00K derived: sum of 2 quarters · filed 2022-11-10 | -$158.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$150.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$143.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$109.00K 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |